HK1200733A1 - Thermosensitive nanoparticle formulations and method of making the same - Google Patents

Thermosensitive nanoparticle formulations and method of making the same

Info

Publication number
HK1200733A1
HK1200733A1 HK15101371.0A HK15101371A HK1200733A1 HK 1200733 A1 HK1200733 A1 HK 1200733A1 HK 15101371 A HK15101371 A HK 15101371A HK 1200733 A1 HK1200733 A1 HK 1200733A1
Authority
HK
Hong Kong
Prior art keywords
making
same
nanoparticle formulations
thermosensitive
thermosensitive nanoparticle
Prior art date
Application number
HK15101371.0A
Other languages
English (en)
Chinese (zh)
Inventor
‧裡德
蘇大水
Original Assignee
Celsion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celsion Corp filed Critical Celsion Corp
Publication of HK1200733A1 publication Critical patent/HK1200733A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15101371.0A 2012-02-17 2015-02-06 Thermosensitive nanoparticle formulations and method of making the same HK1200733A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261600418P 2012-02-17 2012-02-17
PCT/US2013/026453 WO2013123407A1 (fr) 2012-02-17 2013-02-15 Formulations de nanoparticules thermosensibles et leur procédé de fabrication

Publications (1)

Publication Number Publication Date
HK1200733A1 true HK1200733A1 (en) 2015-08-14

Family

ID=48984771

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101371.0A HK1200733A1 (en) 2012-02-17 2015-02-06 Thermosensitive nanoparticle formulations and method of making the same

Country Status (16)

Country Link
US (2) US20130230457A1 (fr)
EP (1) EP2814464B1 (fr)
JP (3) JP2015507019A (fr)
KR (1) KR102161271B1 (fr)
CN (2) CN104203216A (fr)
AR (1) AR090080A1 (fr)
AU (1) AU2013221292A1 (fr)
CA (1) CA2864469C (fr)
ES (1) ES2773299T3 (fr)
HK (1) HK1200733A1 (fr)
MX (1) MX2014009827A (fr)
PH (1) PH12014501866A1 (fr)
RU (1) RU2014133467A (fr)
SG (1) SG11201404979RA (fr)
TW (2) TWI684463B (fr)
WO (1) WO2013123407A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971010B1 (fr) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2015034928A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides chimériques
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
JP6715265B2 (ja) * 2015-05-04 2020-07-01 フェルザンティス アーゲーＶｅｒｓａｎｔｉｓ Ａｇ 膜内外ｐＨ勾配ベシクルを調製する方法
GB201509934D0 (en) * 2015-06-08 2015-07-22 King S College London Nanoparticles
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CN105078892B (zh) * 2015-09-06 2018-05-01 重庆医科大学 阿苯达唑热敏脂质体的制备方法
JP6564873B2 (ja) * 2015-11-02 2019-08-21 富士フイルム株式会社 リポソーム組成物およびその製造方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
IT1230505B (it) * 1988-10-11 1991-10-25 Sicor Spa Procedimento per la conversione della daunorubicina in doxorubicina.
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
AU4990397A (en) * 1996-10-22 1998-05-15 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
AU3467001A (en) * 2000-01-28 2001-08-07 Alza Corp Liposomes containing an entrapped compound in supersaturated solution
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
WO2005002546A1 (fr) * 2003-06-27 2005-01-13 Smithkline Beecham Corporation Compositions liposomales stabilisee de topotecane et procedes
CN101889981A (zh) * 2003-11-20 2010-11-24 Ym生物科学有限公司 包含含有药物成分的亲脂胺的稳定脂质体组合物
JP2008520560A (ja) * 2004-11-15 2008-06-19 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム 組合せ治療
US20060127467A1 (en) * 2004-12-14 2006-06-15 Watkin Kenneth L Nanoparticles for delivery of therapeutic agents using ultrasound and associated methods
TWI388344B (zh) * 2005-08-23 2013-03-11 Celsion Corp 儲存奈米微粒調合物之方法
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
CA2700810A1 (fr) * 2007-09-28 2009-04-02 Universitatsspital Basel Immunoliposomes utilises pour le traitement du cancer
WO2009059450A1 (fr) * 2007-11-05 2009-05-14 Shanghai Jiaotong University Administration de médicament dirigée par un ligand peptidique
WO2009059449A1 (fr) * 2007-11-05 2009-05-14 Celsion Corporation Nouveaux liposomes thermosensibles contenant des agents thérapeutiques
US20110177156A1 (en) * 2007-11-14 2011-07-21 Szoka Jr Francis C Sterol-Modified Amphiphilic Lipids
TWI397428B (zh) * 2009-12-29 2013-06-01 Ind Tech Res Inst 標的第四介白素受體之傳輸系統
WO2011109334A2 (fr) * 2010-03-01 2011-09-09 The Regents Of The University Of California Localisation d'agents dans un site cible comportant une composition et une source d'énergie
US20140227343A1 (en) * 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles

Also Published As

Publication number Publication date
TWI637754B (zh) 2018-10-11
JP6824452B2 (ja) 2021-02-03
TW201841622A (zh) 2018-12-01
CA2864469A1 (fr) 2013-08-22
ES2773299T3 (es) 2020-07-10
CN104203216A (zh) 2014-12-10
JP2020050681A (ja) 2020-04-02
EP2814464B1 (fr) 2019-12-18
US20130230457A1 (en) 2013-09-05
AR090080A1 (es) 2014-10-15
EP2814464A1 (fr) 2014-12-24
JP2018058858A (ja) 2018-04-12
CN106727329B (zh) 2020-11-03
AU2013221292A1 (en) 2014-09-11
US10251901B2 (en) 2019-04-09
US20170080003A1 (en) 2017-03-23
RU2014133467A (ru) 2016-04-10
JP2015507019A (ja) 2015-03-05
EP2814464A4 (fr) 2015-08-05
WO2013123407A1 (fr) 2013-08-22
TWI684463B (zh) 2020-02-11
PH12014501866A1 (en) 2014-11-17
CN106727329A (zh) 2017-05-31
TW201345565A (zh) 2013-11-16
KR102161271B1 (ko) 2020-09-29
KR20140126381A (ko) 2014-10-30
MX2014009827A (es) 2014-09-22
CA2864469C (fr) 2020-07-07
SG11201404979RA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
EP2852381A4 (fr) Compositions de nanoparticules lipidiques ainsi que procédés de fabrication et procédés d'utilisation de celles-ci
AP2014008172A0 (en) Nanocomposite and method of making the same
IL237156B (en) Microcapsule preparation and methods
HK1209079A1 (en) Catalytic forms and formulations
HK1208604A1 (en) Oral care implement and method of forming the same
ZA201602510B (en) Strigolactone formulations and uses thereof
HK1200733A1 (en) Thermosensitive nanoparticle formulations and method of making the same
SG11201405221PA (en) Catheter die and method of fabricating the same
HK1210714A1 (en) Antibody formulations and uses thereof
GB201503017D0 (en) Method and system for the production of nanoparticles
HK1211862A1 (en) Nanoparticle formulation
SG11201404728VA (en) Nanoparticle paste formulations and methods for production and use thereof
ZA201501124B (en) Trans-clomiphene formulations and uses thereof
SG2013081724A (en) Sensor and method of controlling the same
SG11201405941QA (en) Article and method of making the same
PL2922698T3 (pl) Okno termochromowe oraz sposób jego wytwarzania
HK1198833A1 (en) N-acylpeptide derivatives and their uses n-
HK1175159A1 (en) Graphite block and the preparation method thereof
EP2909285A4 (fr) Agents gélifiants et leurs procédés d'utilisation
SG11201500474PA (en) Nutriculture member and nutriculture method
EP2837624A4 (fr) 2-hydroxymorpholine-3-one 4-substituée et son procédé de préparation
HK1199411A1 (en) Nano-emulsion composition and method for producing the same
HK1176343A1 (en) Modified grapheme and preparation method thereof
PL2743282T3 (pl) Produkt kondensacji melaminy z aldehydem i sposób jego otrzymywania
GB201223374D0 (en) Personal care composition and methods of making the same